Cytomx Therapeutics Inc Stock Price, News & Analysis

CytomX Therapeutics announced the completion of a Phase 2 study of praluzatamab ravtansine in patients with HR+/HER2-non-amplified breast cancer, achieving a primary endpoint of a confirmed objective response rate (ORR) of 15%. This study also reported a clinical benefit rate of 40% at 24 weeks and a median progression-free survival of 2.6 months. However, Arm B of the study, targeting triple-negative breast cancer, failed to meet its endpoint, leading to its discontinuation. The company plans to pursue partnerships for further development given current financial conditions.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) granted stock options for 109,000 shares at $1.72 per share to two new employees on June 15, 2022. This grant is part of the Company’s 2019 Employment Inducement Incentive Plan, approved by its board of directors in August 2020. CytomX is advancing conditionally activated oncology therapeutics, including its investigational antibody-drug conjugates praluzatamab ravtansine and CX-2029, which are in Phase 2 studies targeting challenging cancer types.

CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will present at the Jefferies Healthcare Conference on June 8, 2022, at 2:00 p.m. ET. A live webcast of the presentation will be available on CytomX’s website, with an archived replay accessible for 30 days.

CytomX is a clinical-stage biopharmaceutical company focused on conditionally activated cancer therapies. Its pipeline includes investigational drugs like praluzatamab ravtansine and CX-2029, targeting complex cancers. The company partners with leaders in oncology, including AbbVie and Bristol Myers Squibb.

CytomX Therapeutics (Nasdaq: CTMX) has announced the initiation of a Phase 1 dose-escalation study for its investigational bispecific antibody, CX-904, targeting EGFR and CD3 on T cells. This study marks the sixth candidate from CytomX's Probody platform to enter clinical trials, emphasizing its commitment to innovative cancer therapies. The trial aims to improve therapeutic windows in treating solid tumors, leveraging conditionally activated T-cell engagement. Early preclinical models indicate promising potential, and trial results may address unmet needs in multiple tumor types.

CytomX Therapeutics reported significant progress in its clinical studies and financial results for Q1 2022. Patient enrollment in Arm A of the Phase 2 study for praluzatamab ravtansine in breast cancer is complete, with initial data expected in H2 2022. The CX-2029 study's enrollment for squamous non-small cell lung cancer is also complete, with updates anticipated in the same period. The company has $263 million in cash, while revenue increased to $17.1 million. R&D expenses rose to $30.6 million, reflecting ongoing clinical developments.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. markets close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the live webcast on the company’s Events and Presentations page. CytomX, a leader in conditionally activated oncology therapeutics, features a robust pipeline including investigational drugs for various cancer types.

CytomX Therapeutics (Nasdaq: CTMX) announced the impending retirement of John A. Scarlett, M.D. from its board, effective at the next annual stockholder meeting on June 15, 2022. Dr. Scarlett has been on the board since June 2016, contributing significantly to the company as chair of the Compensation Committee. CEO Sean McCarthy highlighted Dr. Scarlett's invaluable biopharma experience during his tenure. CytomX is focused on developing innovative oncology therapeutics, including investigational antibody-drug conjugates and immunotherapeutic candidates targeting difficult-to-treat cancers.

CytomX Therapeutics (CTMX) announced the retirement of Frederick W. Gluck from its board of directors, effective June 30, 2022. Gluck, a co-founder of the company, has been influential since its inception in 2008. His strategic insight has been key in positioning CytomX as a leader in oncology therapeutics. The board will remain robust with eight directors post-retirement, seven of whom are independent under NASDAQ rules. CytomX is recognized for its unique Probody technology, focusing on conditionally activated biologics aimed at improving cancer treatment outcomes.

CytomX Therapeutics (CTMX) announced that it will present preclinical data on its conditionally activated cytokine program at the AACR Annual Meeting from April 8-13, 2022. The data highlights the development of the interferon alpha-2b therapeutic candidate, which aims to enhance the effectiveness of immunotherapy while reducing toxicity. This initiative is part of CytomX's broader strategy to improve treatment options for patients with challenging cancers. The presentation is scheduled for April 11, 2022, and will focus on the therapeutic candidate's potential benefits.